SCHEMBL3986839

SCHEMBL3986839

CCCCCCCCCCCCCCCCCC[Si](C)(C)N

nearest known ligand 0.47

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.47
THRB P10828 1/20 0.47
DNM1 Q05193 9/20 0.43
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
EPHX1 P07099 1/20 0.43
EPHX2 P34913 1/20 0.38
LMNA P02545 2/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29449243 1.00 TSHR (0.47) TSHRTHRBDNM1ALDH1A1MEN1
SCHEMBL29449231 1.00 TSHR (0.47) TSHRTHRBDNM1ALDH1A1MEN1
SCHEMBL1494309 1.00 TSHR (0.47) TSHRTHRBDNM1ALDH1A1MEN1
SCHEMBL29449273 1.00 TSHR (0.47) TSHRTHRBDNM1ALDH1A1MEN1
SCHEMBL1494461 1.00 TSHR (0.47) TSHRTHRBDNM1ALDH1A1MEN1
SCHEMBL1494464 1.00 TSHR (0.47) TSHRTHRBDNM1ALDH1A1MEN1
SCHEMBL1494519 1.00 TSHR (0.47) TSHRTHRBDNM1ALDH1A1MEN1
SCHEMBL1344984 1.00 TSHR (0.47) TSHRTHRBDNM1ALDH1A1MEN1
SCHEMBL1494509 1.00 TSHR (0.47) TSHRTHRBDNM1ALDH1A1MEN1
SCHEMBL29449233 1.00 TSHR (0.47) TSHRTHRBDNM1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109589950-A A kind of preparation method of liquid chromatographic packing materials 上海谱宁分析技术有限公司 2019-04-09 CN claimed
US-20260018421-A1 SUBSTRATE PROCESSING METHOD, AND SUBSTRATE MANUFACTURING METHOD CENTRAL GLASS CO LTD (JP) 2026-01-15 US disclosed
US-20250343040-A1 SUBSTRATE PROCESSING METHOD AND SUBSTRATE PRODUCTION METHOD CENTRAL GLASS CO LTD (JP) 2025-11-06 US disclosed
EP-4535405-A1 SUBSTRATE PROCESSING METHOD AND SUBSTRATE PRODUCTION METHOD Central Glass Company, Limited (JP) 2025-04-09 EP disclosed
EP-4535406-A1 SUBSTRATE PROCESSING METHOD, AND SUBSTRATE MANUFACTURING METHOD Central Glass Company, Limited (JP) 2025-04-09 EP disclosed
CN-113169060-B Chamfering part treating agent composition and method for manufacturing wafer 中央硝子株式会社 2025-04-01 CN disclosed
US-20250066621-A1 COMPOSITION FOR FILM FORMATION AND METHOD FOR MANUFACTURING SUBSTRATE CENTRAL GLASS COMPANY, LIMITED (JP) 2025-02-27 US disclosed
CN-119278504-A Substrate processing method and substrate manufacturing method 中央硝子株式会社 2025-01-07 CN disclosed
CN-119278503-A Substrate processing method and substrate manufacturing method 中央硝子株式会社 2025-01-07 CN disclosed
WO-2024248021-A1 FILM-FORMING COMPOSITION, METHOD FOR PRODUCING SUBSTRATE, AND METHOD FOR PRODUCING FILM-FORMING COMPOSITION セントラル硝子株式会社 2024-12-05 WO disclosed
US-11282709-B2 Chemical agent for forming water repellent protective film and surface treatment method for wafers CENTRAL GLASS COMPANY, LIMITED (JP) 2022-03-22 US disclosed
CN-113058558-B Preparation method of silica gel matrix HPLC (high performance liquid chromatography) filler 中科微分科技发展(北京)有限公司 2021-09-21 CN disclosed
CN-113058558-A Preparation method of silica gel matrix HPLC (high performance liquid chromatography) filler 中科微分科技发展(北京)有限公司 2021-07-02 CN disclosed
CN-109589950-A A kind of preparation method of liquid chromatographic packing materials 上海谱宁分析技术有限公司 2019-04-09 CN disclosed
CN-109589950-A A kind of preparation method of liquid chromatographic packing materials 上海谱宁分析技术有限公司 2019-04-09 CN disclosed
WO-2009059984-A2 REVERSIBLE HYDROPHOBIZATION OF ANTITUMOR DRUGS FOR ENHANCED FIRST-PASS DRUG UPTAKE F. HOFFMANN-LA ROCHE AG (CH) 2009-05-14 WO disclosed
US-20090074885-A1 Reversible Hydrophobic Modification of Drugs for Improved Delivery to Cells ROCHE MADISON INC. (US) 2009-03-19 US disclosed
EP-1663933-A2 IMPROVED DELIVERY BY LABILE HYDROPHOBIC MODIFICATION OF DRUGS Mirus Bio Corporation (US) 2006-06-07 EP disclosed
WO-2005026083-A2 IMPROVED DELIVERY BY LABILE HYDROPHOBIC MODIFICATION OF DRUGS MIRUS BIO CORPORATION (US) 2005-03-24 WO disclosed
US-20050054612-A1 Delivery by labile hydrophobic modification of drugs ROCHE MADISON INC. 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260018421-A1 SUBSTRATE PROCESSING METHOD, AND SUBSTRATE MANUFACTURING METHOD ESPL1, SMS, SGMS1 TSHR 2961/4885THRB 2882/4885DNM1 927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.